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ABSTRACT
Background Hormone replacement therapy increases
the risk of developing ulcerative colitis in
postmenopausal women. Chronic intestinal inflammation
predisposes to colon cancer development, but effects of
female hormones on colitis-associated cancer
development have not been examined.
Aim To investigate the role of female hormones in the
dextran sodium sulfate (DSS)-azoxymethane (AOM)
mouse model for colitis-associated cancer.
Design We performed ovariectomies, or sham
operations, on mice, and supplemented these animals
with indicated hormones. Additionally, we used
oestrogen receptor α or β (Erα or Erβ) mutant mice. To
study colitis or colitis-associated cancer, we used DSS
only, or DSS and AOM, respectively.
Results Ovariectomy protects female mice against
colitis-associated tumour development. Hormone
replacement in ovariectomised mice with either
oestradiol (E2), medroxyprogesterone acetate or a
combination of both suggests that oestrogens are the
ovary-derived factor that promotes tumour development
in the context of inflammatory damage. E2-treated
animals showed increased clinical symptoms and Il-6
production upon DSS-induced colitis and enhanced
epithelial proliferation. Treatment with E2 markedly
increased the numbers of polyps in ovariectomised mice
and also strongly promoted tumour progression with all
E2-treated animals developing at least one invasive
adenocarcinoma, whereas, placebo-treated animals
developed adenomas only. Using Er mutant mice, we
find that the protumorigenic effect of oestrogen depends
on both Erα and Erβ.
Conclusions Our results suggest that oestrogens
promote inflammation-associated cancer development
by impairing the mucosal response to inflammatory
damage.
INTRODUCTION
Patients with inflammatory bowel disease (IBD) are
at an increased risk of developing colorectal cancer
(CRC). The risk of developing CRC correlates with
the duration, extent and severity of inflammation.1 2
Factors driving inflammation-associated cancers are
different from sporadically occurring cancers as
they seem to be driven by a distinct sequence of
DNA mutations.3
One of the important risk factors for the devel-
opment of sporadic adenomas and CRC is male
gender. Women have a delayed development of
adenomas and colon cancers.4 5 This gender dispar-
ity may depend on a protective effect of female
hormones in premenopausal women. The protect-
ive effect of female hormones was suggested by the
outcome of the Women’s Health Initiative. In these
large randomised placebo-controlled trials, the
combination of oestrogen and medroxyprogester-
one acetate (MPA) reduced the number of colon
cancers by 37% compared with placebo at 5 years
follow-up.6 7 Treatment with oestrogens alone did
not significantly affect the risk of colon cancer
development.8 9
Recently, it was shown in a large cohort study, that
the risk of developing IBD is increased in postmeno-
pausal women who were/are past/current users of
female hormones (either oestrogens or oestrogens in
combination with progestins).10 11 However, the role
of female hormones in colitis-associated cancer devel-
opment has not been examined. We therefore set out
to investigate a role for female hormones in an
experimental model for colitis-associated cancer
Significance of this study
What is already known about this subject?
▸ Female hormones increase the risk for
developing inflammatory bowel disease.
▸ Female hormones protect against sporadic
colorectal cancer development.
▸ Oestrogens have known pro- and
antitumorigenic effects.
What are the new findings?
▸ Endogenous female hormones deteriorate
colitis-associated cancer development in vivo.
▸ Of female hormones, oestrogens are
responsible for proinflammatory and
protumorigenic effects.
▸ The effect of oestrogens on development of
colitis-associated cancer depends on both
oestrogen receptors α and β.
How might it impact on clinical practice in
the foreseeable future?
▸ Our data suggest that care should be taken
with prescribing hormone replacement therapy
in women with inflammatory bowel disease.
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development. In line with the data that suggest a predisposing role
for oestrogens in the development of ulcerative colitis, we find that
oestrogens promote tumour incidence and progression in the
context of intestinal inflammation.
MATERIAL AND METHODS
Animal experiments
All experiments were performed according to the guidelines of
the Experimental Animal Center of the Leiden University
Medical Center (PDC), or the Animal Research Institute of the
Academic Medical Center. Erα12 and Erβ13 knockout mice were
ordered at Jacksons Laboratories and bred heterozygously to
generate Erα−/− or Erβ−/− animals. For all experiments, wild-
type littermate control animals were used. All mouse experi-
ments were performed on C57BL/6J background.
Ovariectomy (OVX) was performed on all mice, unless indi-
cated otherwise. For OVX, a sagittal cut of 1 cm was made on
the back of mice. The skin was then manipulated over the fat
pad where the ovarium resides. A small cut was made in the fat
pad, and the ovarium was found and removed by cauterisation.
The fat pad was closed by a single suture and the skin was
closed using staples. Where indicated, a pellet containing either
steroid hormone or placebo (Innovative Research of America)
was implanted subcutaneously in the neck. One week after
surgery, animals were enrolled in the dextran sodium sulfate
(DSS)-azoxymethane (AOM) protocol, or the DSS protocol.
For the DSS-AOM protocol, on day 1, mice were injected
with azoxymethane (10 mg/kg/day; Sigma–Aldrich, Zwijndrecht,
Netherlands), and drinking water was changed for water supple-
mented with 1.5% DSS weight per volume. On day 4, DSS was
refreshed, and on day 6, DSS was changed back for regular
drinking water. A similar cycle of DSS was repeated in week 4
and week 7. At 12 weeks of age, animals were sacrificed and
colons were fixed in phosphate buffered saline (PBS) containing
4% formaldehyde. For the experiment with DSS only, animals
received drinking water supplemented with 2% DSS for 7 days.
On day 8 animals, were sacrificed. One hour prior to sacrifice,
all animals were injected with 200 ml BrdU (10 mg/ml in PBS;
Sigma–Aldrich). Since the severity of DSS-AOM-induced
tumorigenesis tends to vary between different experiments, we
included placebo-treated animals in each experiment.
Hormone replacement
Slow-release pellets with hormones (Innovative Research of
America) were based on an average weight of 25 g/mouse. Pellets
contained the following steroid doses: oestradiol (E2): 0.025 mg
per 90-day slow-release pellet: 10 μg/kg/day. MPA: 7.5 mg per
90-day slow-release pellet: 3.3 mg/kg/day. Placebo pellets were of
similar size, but contained no steroids.
Polyp counting
After overnight fixation of colons, tissue was rinsed with PBS
twice and immersed in 70% ethanol overnight. Subsequently,
polyps were counted. Polyp size was estimated using a ruler
guide.
DSS scoring system
A standardised scoring system was used to assess the severity of
colitis both clinically and histopathologically.14
Tissue processing and immunohistochemistry
Immunohistochemistry was performed as previously described.15
In short, tissue was fixed in 10% ice-cold formalin embedded in
paraffin. Sections of 4 mm were deparaffinised in xylene and
rehydrated. For immunohistochemistry, endogenous peroxidase
was blocked using 0.3% H2O2 in methanol. The sections were
cooked in 0.01 M citrate buffer pH 6.0 for 20 min and incubated
with the primary antibody in PBS with 1% bovine serum albumin
and 0.1% Triton X-100. Antibody binding was visualised with
Powervision horseradish peroxidase-labelled secondary antibodies,
and diaminobenzidine for substrate development. All sections
were counterstained with Mayer’s haematoxylin. The following
antibodies were used: mouse monoclonal anti-BrdU (clone
BMC9318, Roche), rabbit monoclonal anticleaved-caspase 3
(#9664, Cell signalling technologies).
Cytokine bead analysis
Intestines were lysed in nine volumes of Greenberger lysis
buffer using a motorised Turrax homogeniser. The lysis was
made out of a 2× buffer containing 150 mM NaCl, 15 mM
Tris, 1 mM MgCl2, 1 mM CaCl2 and 1% Triton X-100 pH 7.4
prior to use, the 2× buffer was diluted 1 : 1 with 0.9% NaCl,
and to 50 ml buffer 1 tablet protease inhibitor (Roche) was
added. Tissues were homogenised on ice, and after homogenisa-
tion they were put to rest on ice for 30 min. Subsequently, the
lysates were centrifuged for 7 min at 4000 rounds per minute
(RPM) at 4°C in a microcentrifuge. The supernatant was put
into a clean new tube and centrifuged for 10 min at 14 000
RPM at 4°C, and stored at 20°C for further analysis. Cytokine
bead analysis (CBA) was performed on a mouse Th1 cytokine
kit (R&D) according to the manufacturer’s protocol.
Statistical analysis
All data are presented as mean±SE of the mean. For animal
experiments, a Student t test or a 1-way analysis of variance
(ANOVA) test was used. For the analysis of the distribution of
polyp size, 2-way ANOVA tests were used. All ANOVA tests were
followed by Bonferroni’s post-test for multiple comparisons. For
survival analysis, Gehan–Breslow–Wilcoxon values were noted
for comparison, corrected using Bonferroni’s post-test for mul-
tiple comparisons, where p<0.05/K was regarded as significant.
K was defined as the total number of analyses made.
RESULTS
Female hormones promote tumorigenesis in a mouse model
for colitis-associated cancer
To analyse the role of female hormones in intestinal tumorigen-
esis in the context of inflammation, we used the AOM-DSS
model.16 In this model, an injection with the carcinogen AOM
is followed by three subsequent cycles of DSS to induce colitis
(figure 1A). DSS causes direct damage to the colonic epithelium,
eliciting a wound-healing response that markedly enhances
AOM-induced tumorigenesis. We first examined whether female
hormones influence colitis-associated cancer development. In
female mice, endogenous production of female sex hormones
can be largely abrogated by OVX. We therefore subjected
female mice that had undergone OVX, or a sham operation in
which the ovaries where left in situ, to the AOM-DSS model.
During the cycles of DSS-induced colitis, we noticed that
animals in which ovaries had been removed were slightly but
not significantly protected from DSS-induced weight loss (data
not shown). Surprisingly, we found that females who had under-
gone OVX were markedly protected from tumour development
compared with sham operated mice (figure 1B, 7.0 vs 12.0
tumours per colon, p<0.001). Size distribution of the polyps
did not differ between mice that had undergone OVX or a
sham procedure (figure 1C). These data suggest that female hor-
mones promote tumorigenesis in the context of inflammation.
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Colitis-associated tumorigenesis is promoted by oestrogens
We next set out to investigate which ovarian hormone is respon-
sible for the promotion of colitis-associated cancer develop-
ment. Therefore, we induced tumours in mice that underwent
OVX, and in which we replaced endogenous hormones with
slow-release pellets implanted subcutaneously. Animals were
treated with pellets containing the oestrogen oestradiol (E2,
10 μg/kg/day), the progestin (MPA, 3.3 mg/kg/day) or with a
combination of both. MPA is a synthetic progestagen that
signals through the progesterone receptor, and is widely used as
a contraceptive agent. Additionally, MPA in combination with
oestrogen, was shown to be protective in sporadic colon cancer
development in humans.6 7 The concentrations used were based
on the IC50 required for inhibition of ovulation in rats, and
allosterically converted to mice.17 To control for placement of
the pellet, a placebo pellet was implanted in mice that did not
undergo hormone replacement. OVX was performed together
with the placement of the pellets 1 week prior to enrolment in
the AOM-DSS protocol. Animals that received E2, either as
monotherapy or in combination with MPA suffered more
DSS-induced weight loss than control animals or animals that
had received MPA monotherapy (figure 2A, p<0.01 on day 8
for E2 vs placebo, p<0.001 on day 8 for E2+MPA vs placebo).
This resulted in reduced survival of mice that had received E2
(p<0.01), but not for animals that had received the combin-
ation of E2 and MPA (figure 2B). We treated all groups with
1.5% DSS in the drinking water for a period of 5 days in weeks
1, 4 and 7, since this was the highest level of DSS that was toler-
ated in E2-treated mice. Due to the low levels of DSS we gave
to all animals, control mice showed minimal clinical symptoms
(eg, weight loss, diarrhoea and rectal bleeding). Additionally,
control animals developed only few tumours. Mice that received
E2 showed a dramatic 10-fold increase in polyp development
compared with placebo-treated mice (figure 2C,F, 1.5 vs 16
polyps/mouse in placebo and E2-treated mice, respectively,
p<0.001). In agreement with the survival data, animals that had
received MPA together with E2 were partially protected from
E2-induced tumorigenesis (figure 2C, 5.6 polyps/mouse in MPA
+E2-treated mice, p<0.001). E2 promoted tumour incidence
and also tumour progression, as we observed a shift towards
larger polyp size in E2-treated mice (figure 2D, p<0.01). To
examine how E2 affects mucosal homeostasis, we assessed
numbers of proliferating and apoptotic cells in the normal
appearing mucosa at the moment of sacrifice. We found that E2
significantly increased the number of Ki-67 positive cells,
whereas the number of apoptotic (active caspase-3 positive) cells
was very low and unchanged by treatment with E2 (figure 2E).
The polyps were assessed by an expert GI pathologist ( JR) on
one longitudinal microscopic section of the colon of every
animal. It was found that all animals treated with E2 developed
adenocarcinomas with invasive growth (figure 2G), whereas no
adenocarcinomas were observed in any of the animals that had
received placebo (p<0.01 Fisher’s exact test).
To examine if the tumour-promoting effect of oestrogen was
specific to female mice, we also enrolled male mice that had
undergone a sham operation in the AOM-DSS model. Similar to
females, E2 treatment caused enhanced weight loss and
decreased survival in DSS-AOM-treated males (see online sup-
plementary figure S1A,B). Additionally, an increase in tumour
number was seen in males receiving E2 compared with placebo
(see online supplementary figure S1C), albeit to a lesser extent
than in females (3.6±2.7 vs 7.6±3.6, p<0.05). Likewise, a
trend towards larger polyps was observed, although not signifi-
cant (see online supplementary figure S1D). Thus, oestrogens
promote both tumour incidence and growth in the context
of inflammation.
Oestrogens aggravate clinical symptoms of disease, but not
histological severity of colitis
E2-treated mice showed increased weight loss during the cycles
of DSS in the AOM-DSS model. At the time of sacrifice
however, the weight of different treatment groups had reverted
to the levels that had been measured before the start of
DSS-AOM. Weight loss is a sensitive measure of the severity of
Figure 1 Endogenous female
hormones promote colitis-associated
tumorigenesis. (A) Protocol for
induction of colitis-associated tumours
by azoxymethane combined with
dextran sodium sulfate (AOM-DSS).
Mice are injected with 10 mg/kg AOM
on day 1, and colitis is induced by
addition of indicated amounts of DSS
to the drinking water in weeks 1, 4
and 7. Animals are sacrificed for polyp
count 12 weeks after the injection of
AOM. (B) Polyp number of mice that
had undergone ovariectomy (OVX), or
sham operations, prior to AOM-DSS.
(C) Distribution of polyp size after OVX
or a sham procedure **=p<0.01.
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colitis in the DSS model, which in turn is linked to tumorigen-
esis. Thus, increased severity of colitis could explain the
tumour-promoting properties seen in animals treated with
E2. Although previous reports have shown colitogenic effects of
E2, these experiments were performed without OVX, in the
presence of endogenous hormone production.18 We therefore
repeated these experiments and examined if E2 may aggravate
DSS-induced colitis. As in the previous experiment, we sub-
jected mice to OVX and injected these animals with E2 or
placebo pellets. They subsequently received a high dose of DSS
(2.5%) in their drinking water for 7 days.
E2 aggravated colitis development as judged by clinical symp-
toms: weight loss, diarrhoea and rectal blood loss (figure 3A,B,
see online supplementary figure S2A). However we observed no
significant differences in the histopathological score of colitis
that was scored by an expert gastrointestinal pathologist ( JR),
blinded to the treatment of the mice (see online supplementary
figure S2B). As in the AOM-DSS experiment, E2 replacement
increased the rate of proliferation in DSS-treated animals, but
left the number of apoptotic epithelial cells unchanged
(figure 3C). We performed a Th1 cytokine bead array to
examine the influence of oestrogens on a panel of inflammatory
cytokines (Ifnγ, Tnfα, Il-12 p40, Il-6, Il-10, Mcp-1). Ifnγ was
below the level of detection. Of the other cytokines, only Il-6
was significantly increased by oestrogen replacement compared
with animals implanted with placebo pellets (figure 3D,
Figure 2 Oestrogens promote colitis-associated cancer development. Female mice that underwent ovariectomy (OVX), were implanted with
hormone or placebo pellets as indicated, and were subjected to azoxymethane (AOM)-dextran sodium sulfate (DSS). (A) Mice on E2 alone or E2
+medroxyprogesterone acetate (MPA) combination therapy lost significantly more weight than mice implanted with placebo pellets. (B) Mice on E2
replacement therapy after OVX showed significantly decreased survival compared with controls. (C) Polyp counts show that E2 replacement
promotes tumour development in OVX mice in the AOM-DSS model, whereas MPA significantly protects against the tumour-promoting effects of E2.
(D) E2 replacement results in a significant shift towards larger polyps in the AOM-DSS model. (E) E2 replacement increases the number of BrdU
positive cells, but not caspase-3 positive cells. (F) Representative pictures of colons of a mouse from the placebo group versus a mouse on E2
replacement therapy. (G) Representative photomicrographs show H&E section of a small polyp in an animal from the placebo group, and an invasive
adenocarcinoma (arrow head indicates area of invasive growth) in an animal treated with E2 **=p<0.01, ***=p<0.001.
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p<0.01). These results suggest that during DSS-induced inflam-
mation, oestrogens increase clinical severity of inflammation,
which correlates with increased mucosal concentrations of Il-6
and increased epithelial proliferation. However, the gross histo-
logical severity of colitis remains unaltered. These observations
where made in two independent experiments with identical
results.
Oestrogen signalling promotes tumorigenesis through both
Erα and Erβ
E2 signals through two distinct oestrogen receptors (Erα and
Erβ). When E2 binds the receptors, they form homo- or hetero-
dimers, and translocate from the cytosol to the nucleus where
they act as transcription factors. The oestrogen receptors, Erα
and Erβ, are products of different genes localised on different
chromosomes, and with distinct expression patterns. They can
mediate distinct effects of oestrogens and have pleiotropic
effects on cancer development.19
To examine which oestrogen receptor is responsible for the
oncogenic effect of E2 in colitis-associated cancer development,
we bred Erα+/− and Erβ+/− mice and compared homozygous
mutant mice with their littermate wild-type mice in the
AOM-DSS model. Similar to our previous experiments, all
animals were subjected to OVX prior to the start of AOM-DSS,
and mice similarly received slow-release pellets with either E2
or with placebo.
During the DSS cycles in the protocol, wild-type control mice
treated with E2 exhibited marked weight loss compared with
placebo-treated wild-type control mice as expected (p<0.0001
in littermate control animals of both Erα−/− and Erβ−/− mice).
Erα−/− mice were completely protected against the effect of E2
on DSS-induced weight loss (figure 4A). By contrast, weight loss
in Erβ−/− mice was even slightly, though not significantly, higher
than in wild-type control mice (figure 4B). Both Erα−/− and
Erβ−/− mice were protected against the enhanced proliferation
observed in the epithelium of E2-treated wild-type mice
(figure 4C). When analysing polyp numbers, we found that E2
consistently and reproducibly increased the tumour load
throughout our experiments. Despite their distinct effects on
the clinical severity of colitis during the DSS cycles, both Erα−/−
and Erβ−/− mice were protected from E2-induced tumorigenesis
(figure 4D,G). Additionally, E2 consistently and significantly
increased tumour size in wild-type littermate control animals,
but not in Erα−/− and Erβ−/− mice (figure 4E,F and H,I). Taken
together, these results suggest that the tumour-promoting effects
of E2 require both Erα and Erβ. However, there may be differ-
ences in the way in which these receptors modulate tumorigen-
esis. Based on the DSS-induced weight loss, we find that Erα
promotes tumorgenesis by aggravating inflammation, whereas,
Erβ has inflammation-independent effects on tumours in the
context of intestinal inflammation.
DISCUSSION
The large prospective randomised trials of the Women's Health
Initiative have firmly established that hormone replacement
therapy with a combination of oestrogen and MPA protects
against the development of CRC.6–8 Recently, large epidemio-
logical studies have suggested that oestrogens promote the devel-
opment of ulcerative colitis.10 11 We find that ovariectomised
mice are protected against the development of colitis-associated
cancer development. Using different combinations of replace-
ment therapy, we find that oestrogens promote colitis-associated
cancer development. Additionally, oestrogens promote clinical
signs of colitis, such as weight loss and the severity of diarrhoea,
but had no effects on histological scores as judged by H&E stain-
ing. The increased clinical symptoms correlated with elevated
Il-6 production, but levels of Tnfα, Il-12 and Il-10 were not
affected by oestrogens. A colitogenic effect of oestrogens in the
DSS model has previously been reported by others in mice that
had not undergone OVX.18 In these experiments, it was shown
that oestrogens aggravate DSS-induced colitis both clinically and
histologically. In our experiments, we find that oestrogens
increase clinical symptoms but not the histology of colitis.
Potentially, this discrepancy depends on the fact that we used an
approximate 80-fold lower dose of oestrogens in our experi-
ments. Although we find no alterations in the histological colitis
score or in separate features of intestinal histology, animals suffer
from increased clinical disease and show increased secretion of
Il-6. This may suggest that similar to the study of Verdú et al, oes-
trogen increases the inflammatory milieu upon DSS-induced
colitis, which may contribute to carcinogenesis. Interestingly, in
the same study by Verdú et al, oestrogens had a protective effect
Figure 3 Oestrogens increase clinical
disease, but not the histological
severity of colitis. Female mice that
underwent ovariectomy, were
implanted with pellets containing E2
or placebo, and were subsequently
subjected to DSS-induced colitis.
(A) Disease activity index, a score that
includes weight loss, diarrhoea and
rectal blood loss was increased by E2.
(B) Animals receiving E2 suffered
significantly more weight loss than
placebo-treated animals.
(C) Immunohistochemistry shows that
E2 significantly increased the number
of BrdU positive cells in S phase in
E2-treated animals, but did not affect
the low number of apoptotic cells
marked by active caspase-3. (D) E2
promoted the secretion of Il-6 in
DSS-induced colitis *=p<0.05,
**=p<0.01.
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on colitis induced with the hapten dinitrobenzene. This is an
intriguing finding in the light that oestrogens may increase the
risk of ulcerative colitis but not Crohn’s disease in humans. Thus,
the effects of oestrogens may depend on the nature of the inflam-
matory response in both mice and humans. As judged by the dif-
ferent roles of Erα and Erβ in DSS-induced weight loss, it seems
that the two oestrogen receptors may have opposing effects on
the severity of colitis. This could be related to the differential
expressions of the two receptors between the epithelium and
lamina propria cells, a question we did not pursue in this study.
This, however, is an observation that warrants further research
into the role of the oestrogen receptors in the development of
colitis.
Tumour induction with DSS-AOM may vary between experi-
ments due to environmental factors or batch to batch variation
of reagents used. Therefore, we used placebo-treated animals in
addition to oestrogen-treated animals in each experiment. We
find that despite their divergent effects on the severity of clinical
symptoms during colitis, both Erα and Erβ are required for the
tumour-promoting effects of oestrogens. By contrast with litter-
mate control animals, we find that animals lacking either Erα or
Erβ become insensitive to the tumour-promoting effects of oes-
trogens. Interestingly, Erα−/− mice have increased tumour size
compared with control animals in the absence of oestrogens
(placebo-treated ovariectomised mice). This may reflect an
oestrogen-independent function of Erα, since these animals lack
both endogenous and exogenous oestrogens. Our studies con-
trast with a recent report that suggests that Erβ mutant mice
have increased tumour development in the AOM-DSS model of
colitis-associated cancer development.20 In this study, it was
found that Erβ mutant mice have a more rapid tumour develop-
ment compared with wild-type littermates in the AOM-DSS
model. The Erβ mutants had an increased number of tumours at
week 9, whereas tumour load was equal to wild-type mice at
week 16. The most noticeable difference between the two
experimental approaches is the fact that we performed OVX in
Figure 4 Oestrogens promote colitis-associated tumorigenesis through both Erα and Erβ. Female Erα and Erβ mutant and their wild-type
littermate control animals underwent ovariectomy (OVX), and were subjected to azoxymethane-dextran sodium sulfate after replacement with E2 or
a placebo pellet. (A) Weight curve shows that Erα mutant mice were completely protected against the weight loss-promoting effect of E2. (B) In Erβ
mutant mice, there was a trend towards increased weight loss in E2-treated animals compared with placebo. (C) Counting of BrdU-positive cells
shows that absence of both Erα and Erβ protected against the enhanced epithelial proliferation observed in E2-treated mice. (D) Polyp numbers of
wild-type and Erα mutant mice treated with E2 or placebo after OVX. (E) In wild-type animals, E2 replacement significantly promoted tumour
progression. (F) By contrast, in Erα mutant littermates, the distribution of polyp size was similar between E2 and placebo-treated mice. (G) Polyp
numbers of wild-type and Erβ mutant mice treated with E2 or placebo after OVX. (H) In wild-type animals, E2 replacement significantly promoted
tumour progression. (I) By contrast, in Erβ mutant littermates, the distribution of polyp size was similar between E2 and placebo-treated mice
*=p<0.05, **=p<0.01, ***=p<0.001.
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all our studies, thereby abrogating endogenous sex hormone
production, whereas in the study by Saleiro et al, the ovaries
were left in situ. OVX plus oestrogen replacement is often per-
formed in Er mutant mice as the lack of one of the receptors
may modulate oestrogen levels and affect signalling through the
remaining receptor. A well known example is the increased
plasma levels of oestrogens that are present in Erα mutant
mice.21 A similar effect may exist in Erβ mutant mice, as Erβ
plays an important role in the ovaries where it is expressed in
the granulosa cells and regulates granulosa cell differentiation.22
Erβ mutant mice display aberrant regulation of oestrogen pro-
duction by the ovaries22 which may influence outcomes in
animal models. These effects can be circumvented by perform-
ing OVX plus hormone replacement.
In the AOM-DSS model, tumorigenesis depends on
DSS-induced tissue damage and the subsequent epithelial repair. It
has recently been demonstrated that efficient repair of inflamma-
tory mucosal injury is important to prevent ongoing inflammation
and epithelial proliferation.23 This was demonstrated in Egfr
mutant mice which show an impaired epithelial response to a
proinflammatory environment on an Il-10 mutant background
resulting in an exaggerated response to DSS with overexpression
of proinflammatory cytokines, excess weight loss and increased
mortality. The mice showed a particular overexpression of Il-6, a
cytokine that plays a key role in colitis-associated cancer develop-
ment.24 25 This excess production of Il-6 likely plays a key role in
the ongoing proliferative response in both Egfr mutant and
E2-treated mice. Finally, the Egfr mutant mice develop more
tumours on an Il-10 mutant background and show enhanced
tumour progression with development of invasive adenocarcin-
omas. Thus, E2 may promote colitis-associated colon cancer devel-
opment by impairing the resolution of inflammatory injury similar
to Egfrmutant mice.
Increased production of Il-6 in E2-treated mice may be the
result of impaired mucosal repair, but may also be more direct.
It was previously shown that oestrogens promote the production
of Il-6 in peritoneal macrophages in vitro and in vivo.26 Similar
to our own results in these macrophages, oestrogens had no
effect on Il-12 production and only little effect on Tnfα.
26 On
the other hand, the effect of oestrogens on Il-6 production in
the context of colitis is in contrast with studies showing that
oestrogens inhibit Il-6-dependent bone resorption,27 and can
suppress Il-6-dependent tumorigenesis in the liver.28 This sug-
gests that effects of oestrogens on Il-6 production are highly
context-dependent.
In conclusion, we find that oestrogens increase severity of
colitis and colitis-associated cancer development. Both Erα and
Erβ are required for the tumour-promoting role of oestrogens.
The tumour-promoting properties of oestrogens correlate with
increased production of Il-6 and an exaggerated proliferative
response of the colonic epithelium which may indicate that E2
compromises mucosal repair after inflammatory injury. Since
colitis-associated cancer development is a relatively rare occur-
rence, there is no clinical information on the effect of female
hormone replacement in the development of colitis-associated
cancer in humans. Our results seem to suggest, however, that
care should be taken to assure that women with ulcerative
colitis who are on hormone replacement therapy, undergo
adequate colonoscopy screening for colon cancer development.
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